Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects

Abstract

AimsStudies of novel centrally acting drugs in healthy volunteers are traditionally concerned with kinetics and tolerability, but useful information may also be obtained from biomarkers of clinical endpoints. This paper provides a systematic overview of CNStests used with SSRIs in healthy subjects. A useful biomarker should meet the following requirements: a consistent response across studies and drugs; a clear response of the biomarker to a therapeutic dose; a dose-response relationship; a plausible relationship between biomarker, pharmacology and pathogenesis. MethodsThese criteria were applied to all individual tests found in studies of selective serotonin reuptake inhibitors (SSRIs), performed in healthy subjects since 1966, identified with a systematic MedLine search. Separate databases were created to evaluate the effects of single or multiple dose SSRI-studies, and for amitriptyline whenever the original report included this antidepressant as a positive control. Doses of the antidepressant were divided into high-and low-dose ranges, relative to a medium range of therapeutic doses. For each test, the drug effects were scored as statistically significant impairment/ decrease (-), improvement/increase ( + ) or no change ( = ) relative to placebo.Results 56 single dose studies and 22 multiple dose studies were identified, investigating the effects of 13 different SSRIs on 171 variants of neuropsychological tests, which could be clustered into seven neuropsychological domains. Low single doses of SSRIs generally stimulated tests of attention and memory. High doses tended to impair visual/auditory and visuomotor systems and subjective per formance, while showing an acceleration in motor function. The most pronounced effects were observed using tests that measure flicker discrimination (improvement at low doses: 75%, medium doses: 40%, high doses: 43% of studies); REM sleep (inconsistent decrease after medium doses, decrease in 83% of studies after high doses); and EEG recordings, predominantly in alpha (decrease in 60% and 43% of studies after low and medium doses, respectively) and in theta activity (increase in 43% and 33% of studies after medium and high doses, respectively). Amitriptyline generally impaired central nervous system (CNS) functions, which increased with doses. Multiple doses caused less pronounced effects on the reported tests. The most responsive tests to amitriptyline appeared to be EEG alpha and theta, and REM sleep duration. ConclusionsSSRIs in healthy subjects appear to cause slight stimulating effects after low doses, which tend to diminish with dose. The most consistent effects were observed with flicker discrimination tests, EEG (alpha and beta bands), REM sleep duration, and subjective effects at higher doses. These effects are small compared with amitriptyline and other CNS-active drugs. Multiple dosing with SSRIs caused even fewer measur-G. J. H. Dumont et al. 49659 :5 Br J Clin Pharmacol

Functional biomarkers for the acute effects of alcohol on the central nervous system in healthy volunteers

“…Based on previous reviews [7][8][9][10][11], it was anticipated that in most cases no consistent quantitative results could be obtained from individual tests, because of the large diversity of methods, parameters and treatments.Therefore, the ability of a test to detect a statistically significant difference from placebo or baseline was scored as '+' (improvement/ increase), '=' (no significant effect) or '-' (impairment/ decrease). Subjective assessments of effects that were signs of improved CNS function or that most users would consider pleasurable (e.g.…”

“…The ability to show clear dose-response relationships is an important requirement for a meaningful drug-effect biomarker [7][8][9][10][11]. The dose also determines the sensitivity of a test for a drug, and the chance to detect an effect.…”

Quantitative EEG Abnormalities are Associated With Memory Impairment in Recently Abstinent Methamphetamine-Dependent Individuals

“…For example, in samples of healthy control subjects, alterations in serotonergic, 22 dopaminergic, 23 and cholinergic 24 function were associated with changes in theta function and neurocognition. These studies suggest an approach for determining the specific neurochemical changes that underlie theta and neurocognitive abnormalities in methamphetamine users.…”

Medication Prediction with Electroencephalography Phenotypes and Biomarkers

“…Or is this one of the 10%-24% of the ADHD population who has unexpected epileptiform or paroxysmal EEG activity who will respond to anticonvulsant medication, and if so, which one? For some cases of ADHD, there is even a chance a client will respond to the selective serotonin reuptake inhibitor (SSRI) class of drugs including Prozac and Zoloft (Dumont, de Visser, Cohen, & van Gerven, 2005) or to the serotonin and norepinephrine (SNRI) drugs such as Effexor or its newer isomer Pristiq. Occasionally, lithium may be provided for hyperkinetic behavior, as though it were related to bipolar disorder.…”